A New, Stronger GLP-1 Is Currently in Clinical Trials. Here's What Researchers Want You to Know
Yahoo Health reports on retatrutide, an investigational Eli Lilly drug targeting GLP-1, GIP and glucagon receptors that is nearing the end of phase 3 trials and is not FDA approved. A trial investigator says weight loss can reach about 28 percent over two years. Experts describe safety so far as similar to existing GLP-1s, while flagging heart rate, skin sensation, muscle, bone and gallbladder questions, and gray-market risks.
Why it matters: Relevant to Maryland adults with clinical obesity who are weighing medical weight loss or bariatric surgery, and to the clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to health.yahoo.com. October 10, 2026.
